Abstract: Certain anti-viral compounds, pharmaceutical compositions, and methods related thereto are disclosed.

Abstract: A method for preparing the cyclic phosphonate compound of Formula I is described. The method significantly improves the stereoselectivity of the compound with the required configuration.

Abstract: Certain anti-viral compounds, pharmaceutical compositions, and methods related thereto are disclosed.

Abstract: The present application describes GLP-IR modulating compounds that are useful for treating GLP-IR-mediated diseases or conditions.

Abstract: A method for preparing the cyclic phosphonate compound of Formula I is described. The method significantly improves the stereoselectivity of the compound with the required configuration.

Abstract: Certain anti-viral compounds, pharmaceutical compositions, and methods related thereto are disclosed.

Abstract: Certain anti-viral compounds, pharmaceutical compositions, and methods related thereto are disclosed.

Abstract: Provided are a method of treating or preventing infection with hepatitis B virus in a human or animal, comprising administering to the human or animal in need thereof a therapeutically effective amount of a phenylisoxazolyl methylene-naphthalene-ether derivative having a structure of formula (I); use of a phenylisoxazolyl methylene-naphthalene-ether derivative having a structure of formula (I) in the preparation of a pharmaceutical composition for anti-hepatitis B vims and a pharmaceutical composition for anti-hepatitis B virus.

Abstract: Certain anti-viral compounds, pharmaceutical compositions, and methods related thereto are disclosed.

Abstract: Certain anti-viral compounds, pharmaceutical compositions, and methods related thereto are disclosed.

Abstract: Provided are a compound for modulating the activity of FXR having a structure of formula (I), a pharmaceutically acceptable salt, an ester or a stereoisomer thereof.

Abstract: A method for preparing the cyclic phosphonate compound of Formula I is described. The method significantly improves the stereoselectivity of the compound with the required configuration.

Abstract: A method for preparing the cyclic phosphonate compound of Formula I is described. The method significantly improves the stereoselectivity of the compound with the required configuration.

Abstract: A method for preparing the cyclic phosphonate compound of Formula I is described. The method significantly improves the stereoselectivity of the compound with the required configuration.

Abstract: The present invention provides a pharmaceutical composition for treating viral hepatitis C, comprising ravidasvir (ASC16) or a pharmaceutically acceptable salt thereof and danoprevir (ASC08) or a pharmaceutically acceptable salt thereof. The combined use of ASC16 and ASC08 has an enhanced effect, and the experimental results show that ASC16 and ASC08 can form an effective combined anti-HCV treatment regimen. Moreover, the administration regimen of ASC16 in combination of ASC08 further expands the action spectrum of therapeutic drugs. More importantly, the combined use of ASC16 and ASC08 solves the problem of drug resistance.

Abstract: The present invention discloses a salt form, crystal form and intermediate of the compound 1, and preparation method thereof.

Abstract: Disclosed is a novel anti-enterovirus 71 (EV71) 1,2,5-thiadiazolidine-1,1-dioxide derivative or a pharmaceutically acceptable salt thereof, and specifically, a compound represented by formula (II) or a pharmaceutically acceptable salt thereof.

Abstract: The present invention discloses a salt form, crystal form and intermediate of the compound 1, and preparation method thereof.

Abstract: Disclosed is a novel anti-enterovirus 71 (EV71) 1,2,5-thiadiazolidine-1,1-dioxide derivative or a pharmaceutically acceptable salt thereof; and specifically, a compound represented by formula (II) or a pharmaceutically acceptable salt thereof.